Related Experiment Video

Updated: Jul 17, 2026

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven

Timothy Wiltshire1, Jamie Senft, Yutian Wang

  • 1Department of Microbiology, Immunology and Cell Biology, West Virginia University School of Medicine, Morgantown, WV 26506-9300, USA.

Molecular Pharmacology
|January 19, 2007
PubMed

Insights

The anticancer drug irofulven causes DNA double-strand breaks. BRCA1 (breast cancer gene) is crucial for repairing this damage and maintaining genomic stability, with its deficiency increasing sensitivity to irofulven.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • BRCA1 is a tumor suppressor gene vital for genomic stability, DNA repair, and cell cycle control, frequently mutated in hereditary breast and ovarian cancers.
  • Irofulven is a novel anticancer agent effective against various tumors, but its precise DNA damage mechanisms remain unclear.
  • Previous studies indicated irofulven activates ATM and related DNA damage response proteins.

Purpose of the Study:

  • To investigate if irofulven induces DNA double-strand breaks.
  • To determine the role of BRCA1 in cellular response to irofulven treatment, focusing on cell cycle checkpoints, DNA repair, and genomic stability.

Main Methods:

  • Assessing irofulven-induced DNA damage markers like chromosome breaks, radials, and gamma-H2AX foci.
  • Evaluating the activation and foci formation of BRCA1 and RAD51.
  • Comparing cellular responses to irofulven in BRCA1-deficient versus BRCA1-proficient cells.

Main Results:

  • Irofulven treatment induced DNA double-strand breaks, evidenced by chromosome aberrations and gamma-H2AX, BRCA1, and RAD51 foci.
  • BRCA1 was essential for controlling S and G(2)/M cell cycle arrest following irofulven exposure.
  • BRCA1 deficiency impaired DNA double-strand break repair and RAD51-dependent homologous recombination, leading to increased chromosome damage and chemosensitivity.

Conclusions:

  • Irofulven induces DNA double-strand breaks, activating DNA damage response pathways.
  • BRCA1 plays a critical role in the cellular response to irofulven by facilitating DNA repair and maintaining genomic integrity.
  • BRCA1 status significantly influences chemosensitivity to irofulven, suggesting potential for targeted therapies.

More Related Videos

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA108:53

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...